Regulatory press release

KDventures AB subscribes for all of its warrants of series 2025/2026 in Modus Therapeutics

Modus Therapeutics Holding AB (publ) (“Modus” or the “Company”) notes that the Company’s largest shareholder, KDventures AB (“KDventures”), has today announced that it subscribes for all of its warrants of series 2025/2026 in the Company.

The subscription period for warrants of series 2025/2026 runs from 13 April to 24 April 2026.

The warrants in brief

• One (1) warrant of series 2025/2026 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.35 per share
• Upon full exercise of all warrants of series 2025/2026, the Company will receive approximately SEK 10 million before transaction costs
• KDventures exercises all of its warrants, corresponding to approximately 51.7 percent of the total number of outstanding warrants, equivalent to approximately SEK 5.1 million

KDventures’ ownership in Modus amounts to approximately 55.7 percent.

Comment from Modus Therapeutics

“We welcome KDventures’ decision to exercise all of its warrants. This is a clear confirmation of their continued commitment to the Company.”
– John Öhd, CEO, Modus Therapeutics

About Modus Therapeutics and sevuparin
Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.